
Ebenbuild builds patient-specific digital twin software of the lung for intensive-care clinicians and pharmaceutical companies.
ebenbuild.comCrawled Nov 4, 2026
Precision therapy based on personalized digital twins
Ebenbuild validates its patient-specific lung digital twin technology in a *Nature Communications Medicine* study. The research demonstrates high-resolution predictive performance for inhaled drug transport and regional deposition across the entire human lung. The model integrates subject-specific airway anatomy to assess locally delivered drug doses.
Ebenbuild secures a **€2.3 million EIC Accelerator grant** to expand its **digital twin platform**, focusing on respiratory health applications. The funding supports the launch of **TwinHale**, the first **in silico trial software** for pulmonary drug delivery. The EIC also commits up to **€10 million** in future equity financing for the company’s growth.
Ebenbuild, a startup spun out from the Technical University of Munich (TUM), appears on *Global University Venturing*'s list of the 12 most notable university spinouts of 2022. The selection highlights high-potential ventures from prestigious institutions worldwide, including Harvard, MIT, and Cambridge.
Global University Venturing highlights 12 university-backed startups from 2022 that demonstrate innovation potential. These spinouts emerge from academic research and institutional support, targeting industries like biotech, cleantech, and AI. The list includes ventures developing novel medical therapies, sustainable materials, and advanced computing solutions. Each startup leverages university resources to accelerate commercialization of breakthrough technologies.
Ebenbuild develops personalized digital twin lung models using patient data to improve Acute Respiratory Distress Syndrome (ARDS) treatment. The Munich-based HealthTech startup raised a €2.5 million seed round led by Bayern Kapital and High-Tech Gründerfonds, with additional business angel participation.